Experiences in fosfomycin susceptibility testing and resistance mechanism determination in Escherichia coli from urinary tract infections in the UK by Cottell, Jennifer L & Webber, Mark A
1 
 
Experiences in fosfomycin susceptibility testing and resistance mechanism 1 
determination in E coli from urinary tract infections in the UK 2 
 3 
Jennifer L. Cottell1†, Mark A. Webber2,3#  4 
 5 
1Department of Microbiology, Northampton General Hospital NHS Trust, Cliftonville, 6 
Northampton NN15BD, UK 7 
 8 
2Quadram Institute, Norwich Research Park, Colney Lane, Norwich, NR4 7UA. 9 
3Norwich Medical School, Norwich Research Park, Colney Lane, Norwich, NR4 7TJ. 10 
†: Present address: Micropathology Ltd, University of Warwick Science Park, Venture 11 
Centre, Sir William Lyons Road, Coventry, CV4 7EZ. 12 
 13 
#mark.webber@quadram.ac.uk 14 
01603255233 15 
 16 
 17 
Running title: UK fosfomycin resistance in E. coli  18 
 19 
 20 
  21 
2 
 
Abstract 22 
Purpose:  As numbers of bacterial isolates resistant to first line antibiotics rise there 23 
has been a revival in the use of older drugs including fosfomycin with novel 24 
mechanisms of action. We aimed to investigate the prevalence and the genotypic 25 
nature of fosfomycin resistance in E. coli from urinary tract infections (UTI) using the 26 
various methods available in the clinical microbiology laboratory.  27 
Methodology: 1000 culture positive urine samples were assessed for the presence of 28 
E. coli and fosfomycin susceptibility was determined using the MAST Uri®system, 29 
microbroth dilution, agar dilution and E-test strips. 30 
Results/Key findings: Initial investigation using breakpoint susceptibility testing on the 31 
MAST Uri®system, deemed 62 of 657 (9.5%) E. coli as fosfomycin resistant (MIC 32 
≥32 µg/ml) However, on further testing, a lower rate of 8 of the 62 (1.3%) were 33 
robustly confirmed to be resistant using micro-broth dilution, agar dilution and E-test 34 
strips These true resistant isolates belonged to diverse E. coli MLST types and each 35 
had a unique set of chromosomal alterations in genes associated with fosfomycin 36 
resistance. Fosfomycin resistant isolates were not multiply drug resistance and did 37 
not carry plasmidic fosfomycin resistance genes. Therefore, the use of fosfomycin 38 
may be unlikely to drive selection of a particular clone or movement of transferrable 39 
resistance genes. 40 
Conclusion: Fosfomycin remains a viable option for the treatment of E. coli in 41 
uncomplicated UTIs, different susceptibility testing platforms can give very different 42 
results regarding the prevalence of fosfomycin resistance with false positives a 43 
potential problem that may unnecessarily limit use of this agent. 44 
Keywords: Fosfomycin; Susceptibility testing; Antibiotic Resistance 45 
  46 
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1.1 Introduction 47 
Globally, increasing numbers of infections are caused by bacteria resistant to current 48 
antibiotics.(1) As there is a lack of new antibiotics in development, the revival of older 49 
drugs with distinct methods of action has been proposed as a short-term solution.(2) 50 
One such drug is fosfomycin, a phosphonic-acid derivative cell wall inhibitor with a 51 
novel mode of action and a broad spectrum of activity. (3) . In Enterobacteriaceae, 52 
fosfomycin is taken up by mimicking the natural substrates of two nutrient transport 53 
uptake systems GlpT and UhpT (inducible in the presence of glucose-6-54 
phosphate);(4) systems which require cyclic AMP (cAMP), cAMP-receptor protein 55 
complexes and activator genes such as uhpA.(5-7) Once in the bacterial cytosol, 56 
fosfomycin acts as a phosphoenolypyruvate analogue preventing the initial step of 57 
cell wall synthesis, via inhibition of MurA.(4) leading to the prevention of 58 
peptidoglycan biosynthesis and cell death.(8) As fosfomycin acts prior in the 59 
biosynthesis pathway to other cell wall inhibitors β-lactams and glycopeptides it is not 60 
inhibited by resistance determinants which act against these drugs such as extended 61 
spectrum beta-lactamases (ESBLs).(9)  62 
Historically the most commonly documented mechanism of fosfomycin resistance 63 
has been impaired transport of fosfomycin into the cytoplasm, due to mutations in 64 
structural or regulatory genes of the nutrient transport systems.(10); for example in 65 
E. coli, insertions, deletions or mutations leading to amino-acid changes in glpT, uhpT 66 
or uhpA. Alternatively, mutations in genes encoding adenylcyclase (cyaA) and 67 
phosphotransferses (ptsI) are known to decrease intracellular levels of cyclic-AMP, 68 
reducing the expression of glpT and uhpT and, consequently intracellular fosfomycin 69 
levels.(11) Mutations in the gene encoding the drug target MurA, particularly those 70 
that confer amino-acid changes in the active site and Cys115 residue have been 71 
demonstrated to decrease the susceptibility of the organism by reducing its affinity 72 
for fosfomycin.(12-14); however these are rare in nature and may impair bacterial 73 
fitness.(10) Over-expression of murA has also been found both in mutants selected 74 
in-vitro and in clinical isolates. It has been suggested this mechanism acts to saturate 75 
fosfomycin molecules thereby allowing normal cellular function.(15, 16)  76 
A final and, perhaps emerging mechanism of resistance is the acquisition of enzymes 77 
that can inactivate fosfomycin by catalysing the opening of its oxirane ring.(17, 78 
18(19))   79 
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Data from multiple studies has shown that exposure to fosfomycin in-vitro rapidly 80 
selects resistant mutants, at a frequency of 10-7-10-8.(20, 21) However, mutants 81 
selected experimentally are typically physiologically impaired; with decreased growth 82 
rates in culture media and urine when compared to wild-type strains.(20) It is also 83 
thought that fosfomycin resistant isolates may have a reduced ability to adhere to 84 
uroepithelial cells or catheters, and to have a higher sensitivity to polymorphonuclear 85 
cells and serum complement killing.(22) Therefore, it has been speculated that 86 
despite the rapid development of resistance in-vitro, significant biological fitness costs 87 
prevent the establishment and propagation of resistant strains in-vivo. (2, 20)  88 
In Japan, Spain, Germany, Austria, France, Brazil, North America and South Africa, 89 
fosfomycin has been used extensively for >30 years(23). In these regions a soluble 90 
salt form called fosfomycin-tromethamine (typically given as a single 3 g oral dose) is 91 
widely used in the treatment of uncomplicated UTIs.(24) Until recently, fosfomycin-92 
trometamol was not distributed or commercially available in the UK; and any products 93 
used were imported, and therefore unlicensed. Despite this, the NHS recorded a ten-94 
fold increase in fosfomycin-trometamol prescriptions from 100 to 1000 between 2012 95 
and 2013; (25) and a further increase to 2,400 prescriptions in 2014. (25)   96 
Renewed interest in fosfomycin has been for treatment of MDR organisms causing 97 
UTIs where oral therapy choices may be limited. Considering these factors and the 98 
possibility of introducing fosfomycin preparations into our formulary, our first aim was 99 
to determine the proportion of organisms isolated from routine UTIs culture deemed 100 
resistance to fosfomycin. In doing so the various methods of measuring susceptibility 101 
to fosfomycin available to our clinical laboratory were assessed, and their relative 102 
merits considered. The second aim was to investigate mechanisms of fosfomycin 103 
resistance.   104 
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1.2 Materials and Methods 105 
1.2.1 Bacterial isolates 106 
Between July and August 2014, 2800 urine specimens received as part of standard 107 
patient care (over 18 days in total) at Northampton General Hospital, a large 700 bed 108 
tertiary hospital in the UK were collected. Subsequent analysis of isolates and 109 
susceptibility testing followed the laboratory work-flow and methodologies used for 110 
clinical investigation of specimens in this trust. Each was examined for signs of 111 
infection using Iris IQSprint microscopy and those specimens meeting conventional 112 
clinical criteria were cultured using the MAST Uri®system (n=1000) as per the 113 
manufactures instructions. The susceptibility status of each cultured isolate to 114 
fosfomycin was determined using a 96-well ‘breakpoint’ agar plate containing 32 115 
µg/ml fosfomycin supplemented with 25 µg/l of glucose-6-phosphate (G6P) as 116 
provided by MAST, and a presumptive species identification was carried out by 117 
determining the colour of colonies growing on MAST CUTI chromogenic agar. A total 118 
of 62 isolates putatively identified as fosfomycin resistant E. coli then had their 119 
species confirmed using MALDI-TOF and were retained for further study. E. coli J53-120 
2 (NCTC 50167) was used as a fosfomycin susceptible control; E. coli NCTC 10418 121 
was used as a quality control for susceptibility testing; and E. coli MG1655 (ATCC 122 
700926) was used as a reference strain for genome comparisons.  123 
1.2.2 Antimicrobial susceptibility testing 124 
The minimum inhibitory concentrations (MIC) of an extended panel of antimicrobials 125 
were determined using the BD PhoenixTM automated microbiology system with 126 
antimicrobial susceptibility testing panel UNMIC-409 as per the manufacturer’s 127 
instructions. Fosfomycin MICs were further determined using fosfomycin E-tests® 128 
(bioMérieux) and using the agar dilution method following the British Society of 129 
Antimicrobial Chemotherapy (BSAC) guidelines.(26)  130 
1.2.3 Whole genome sequencing (WGS) and post sequencing analysis 131 
Isolates consistently considered resistant by all susceptibility testing methods were 132 
genome sequenced by MicrobesNG using an Illumina MiSeq system. Velvet (Version 133 
1.2.10)(27) was used for de-novo assembly of the genomes, and Prokka (Version 134 
1.11)(28) used for annotation. Reads were also analysed using the ‘nullarbor‘ pipeline 135 
(v1.2) using a standard virtual machine on the MRC CLIMB framework. Pan genomes 136 
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were generated using ‘roary‘ (v8.0), SNPs called with ‘snippy‘ (v3.0) and antibiotic 137 
resistance genes and mutations identified using ‘ARIBA‘ (v2.8.1). Trees were 138 
visualised with ‘Phandango‘. All packages used default parameters unless stated 139 
otherwise. The Centre for Genomic Epidemiology 140 
(http://www.genomicepidemiology.org/) provided software for interrogation of 141 
genomes for multi-locus sequence type (MLST), E. coli serotype, plasmid replicons 142 
and resistance associated genes (ResFinder); the Comprehensive Antibiotic 143 
Resistance Database (CARD) was additionally used to seek resistance 144 
determinants.(29)  145 
 146 
  147 
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1.3 Results 148 
1.3.1 Fosfomycin resistance in UTI isolates using MAST urisystem 149 
From 1000 UTI culture positive isolates, 657 were confirmed as E. coli and 62 (9.5%) 150 
were deemed fosfomycin resistant using breakpoint plates on the MAST Uri®system, 151 
with growth on ≥80% of the culture well indicating an MIC >32 µg/ml.  152 
1.3.2 Determination of fosfomycin minimum inhibitory concentrations  153 
1.3.2.1 Fosfomycin MICs using BD PhoenixTM 154 
Using an automated micro-broth dilution method (BD PhoenixTM) 53/62 E. coli 155 
isolates (85.5%) were found to have fosfomycin MICs of <16 µg/ml, three isolates 156 
had an MIC of 32 µg/ml (4.8%) and six isolates had an MIC of 64 µg/ml (9.7%). 157 
Therefore only six isolates showed concordance with data from the MAST 158 
Uri®System, and were deemed resistant using BD interpretative software 159 
(EpicentreTM) with EUCAST breakpoints (>32 µg/ml).(30)  160 
1.3.2.2 Fosfomycin MICs using E-tests 161 
Due to the discrepancy between micro-broth dilution and breakpoint plate MIC 162 
methods, E-tests were used as an alternative method for measuring fosfomycin MICs. 163 
Two susceptible control strains, E. coli J53-2 and E. coli NCTC-10418 grew with 164 
definitive zones of inhibition, revealing MICs of 0.25 µg/ml. Similarly, six selected 165 
isolates deemed resistant using the MAST Uri®system but susceptible using the 166 
micro-broth dilution (BD PhoenixTM) were found to be sensitive to fosfomycin using 167 
E-tests; each growing with a single defined zone of inhibition and MICs ranging from 168 
0.19-0.75 µg/ml (Table 1).  169 
All the isolates deemed resistant by both Mast Uri®system and BD PhoenixTM were 170 
also categorised as resistant using E-test. Despite agreement of a resistance 171 
interpretation between the three methods, there was little concordance between the 172 
specific MICs determined by E-tests and the micro-broth dilution method (Table 1). 173 
Of note was the difficulty in reading and interpreting E-tests. In each test a small 174 
number of single colonies were observed within the clearance zone. As 175 
recommended by others who have recorded the same phenomenon,(31) these 176 
colonies were excluded from the E-test interpretation.  Five isolates had a visible 177 
‘intermediate’ zone of noticeably less dense growth, presenting two possible 178 
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interpretations. Due to the semi-confluent nature of the growth in these regions they 179 
were not included in the zone of inhibition when reading the strips (Table 1).  180 
1.3.3.3 Investigation of fosfomycin MICs using modified agar dilution 181 
To further explore the differing growth phenotypes when using E-tests, a modified 182 
agar dilution method was used whereby colonies were streaked on agar containing 183 
different concentrations of fosfomycin and their growth observed. For the control 184 
organisms and six PhoenixTM/E-test determined fosfomycin susceptible organisms, 185 
either no growth, or single colony/scanty growth was observed on agar containing a 186 
low concentration of fosfomycin (≤ 16 µg/ml). Each of the nine resistant isolates 187 
cultured on a low concentration of fosfomycin produced uniform colony morphologies; 188 
when grown in the presence of higher concentrations of fosfomycin however each 189 
produced a ‘dual colony’ growth phenotype.  190 
1.3.4 Characterisation of selected E. coli isolates 191 
WGS was used to characterise eight of the consistently fosfomycin resistant isolates 192 
and two, randomly selected susceptible isolates. Fosfomycin resistance was present 193 
in several different E. coli sequence types (6 different STs were seen in the 8 resistant 194 
isolates, ST131 was the only ST seen more than once) indicating that resistance was 195 
not distributed due to clonal expansion of one strain (Figure 1 and Table 2). The E. 196 
coli sequence types found in this study include those previously reported as common 197 
in UTI isolates in the UK; ST69, 73, 95 and 131.(32) 198 
Each of the ten isolates were further characterised by investigating their antibiogram, 199 
determined from their susceptibility profile to antimicrobials used in the treatment of 200 
UTIs; and by interrogating WGS for genes and mutations known to confer 201 
antimicrobial resistance (Table 2). Ampicillin resistance was detected in 8/10 isolates, 202 
accompanied with the in-silico detection of blaTEM-1B. Sulfamethoxazole resistance in 203 
5/10 isolates corresponded with the detection of a dfrA gene and with either sul1 or 204 
sul2. Aminoglycoside resistance genes were identified in five of the isolates; of note 205 
was a ST131 isolate possessing gentamicin resistance gene aac(3)-IId along with a 206 
ciprofloxacin resistance conferring mutation in gyrA. 207 
The in-silico analysis also showed the presence of many common 208 
Enterobacteriaceae plasmid replicons including those of incompatibility group, IncF, 209 
IncQ, IncX1, IncB/O/K/Z and plasmids from the group Col and Col156. Using CARD, 210 
Resfinder and manual searches, no fos-like genes were detected in any of the strains, 211 
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suggesting an absence of known plasmid based transferrable fosfomycin resistance 212 
genes in the resistant isolates. 213 
1.3.5 Amino-acid variation in proteins associated with fosfomycin resistance 214 
For each of the ten sequenced isolates, amino-acid changes or mutations in known 215 
fosfomycin resistance genes murA, glpT, uhpT, uhpA, ptsI and cyaA were identified 216 
from the WGS using E. coli MG1655 as a reference (Table 3). No murA changes 217 
were identified in any of the fosfomycin resistant isolates, a single substitution of 218 
Val389Ile was found in susceptible isolate, MU723432.  219 
All sequenced isolates were found to have a Glu448Lys change in GlpT when 220 
compared to MG1566. Fosfomycin resistant isolate MU721372 had an additional 221 
three substitutions of Leu297Phe, Thr348Asn, Glu443Gln, however susceptible 222 
isolate MU724857 also had a second GlpT change of Ala16Thr. 223 
No amino-acid changes in the sequence of UhpT were identified in fosfomycin 224 
susceptible isolates; however, 5/8 resistant isolates had changes in this protein. In 225 
MU720214, both uhpT and uhpA were completely absent. Comparative analysis 226 
against other E. coli genomes showed the presence of a phage integrase gene 227 
adjacent to the uhpT-uhpA region within the assembled contig, suggestive of a 228 
deletion event. Isolate MU720350 had two amino-acid changes at positions 31 and 229 
39 predicted to confer premature stop codons leading to a truncated protein; four 230 
strains had a Glu350Gln amino-acid substitution; and MU723240 had additional 231 
substitutions of Tyr32Asn and Arg325Leu.  232 
Only three isolates had changes in the uhpA gene, a deletion in MU720214, an 233 
Arg46Cys substitution in susceptible isolate MU724857, and substitutions Arg14Gly 234 
and Ala110Ser in fosfomycin resistant isolate MU721372 (Table 3).  235 
When examining genes that affect levels of intracellular cAMP, all the isolates had 236 
the substitution of Arg367Lys in PtsL and Asn142Ser in CyaA when compared to 237 
MG1655; both changes are well represented in many E. coli. Two further substitutions 238 
were identified in PtsL, Val25Ile in two of the resistant isolates (MU723051 and 239 
MU723320) and Ala306Thr in one resistant (MU720214) and one susceptible E. coli 240 
(MU724857). The amino-acid sequences of CyaA in each isolate fell broadly into two 241 
groups, those with a single Asn142Ser change when compared to MG1655 (n=4), 242 
and those with ≥3 additional amino-acid substitutions (Ser352Thr, Ala349Glu, 243 
Ser356Lys, Gly359Glu and Ile514Val) (n=5 Table3) both containing susceptible and 244 
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resistant isolates. These amino-acid substitutions appeared to correlate more closely 245 
with sequence type than with fosfomycin susceptibility status and were found 246 
commonly in other E. coli strains.   247 
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1.4 Discussion 248 
To investigate the extent of fosfomycin resistance in UTI isolates from routine clinical 249 
specimens, different methods available to distinguish susceptible and non-250 
susceptible isolates using clinical laboratory protocols were explored. Use of 251 
‘breakpoint’ plates on the MAST Uri®system for high throughput screening 252 
determined the prevalence of resistance (MIC ≥32 µg/ml) in E. coli isolates as 12%; 253 
a rate significantly higher than previously documented(33-35). However, on further 254 
examination using automated micro-broth dilution, only nine of these isolates were 255 
resistant (MIC ≥32 µg/ml). Furthermore, if CSLI guidelines had been applied none of 256 
the isolates would be deemed resistant, as each had an MIC below the breakpoint 257 
according to this scheme (S≤64, I=128 and R ≥256 μg/ml). (36, 37) Susceptibility 258 
interpretations from the E-test method corroborated the findings from micro-broth 259 
dilution, concordantly differentiating isolates deemed fosfomycin susceptible and 260 
resistance. Therefore, both these methods agree that only 1.3% of E. coli within the 261 
study should be regarded as fosfomycin resistant using current definitions; a 262 
prevalence more in line with findings of previous studies both globally and within the 263 
UK.(37, 38)  The high prevalence of resistance recorded by the MAST Uri®system 264 
reflects a large number of false positive results (53/62) given the interpretive criteria 265 
followed. Whilst changes to fosfomycin susceptibility can occur relatively rapidly in-266 
vitro it is infeasible that a significant number of isolates initially identified as resistant 267 
would have reverted to susceptibility in the time window of the laboratory 268 
investigations. There may also however have been some false-susceptible results 269 
given the methodologies we used  270 
In the collection period, fosfomycin was not used in the trust or by community 271 
pharmacists in this area, therefore patient exposure to the drug is likely to have been 272 
low, and a 1.3% rate of resistance is likely to reflect spontaneous mutants which are 273 
in the wider population of E. coli. Given the reports of fosfomycin resistance incurring 274 
a significant fitness cost (10, 20) this level may be higher than expected given the 275 
probable lack of direct selection in this population. 276 
Lu et al (39) discussed the usefulness of disc-diffusion assays (39) in distinguishing 277 
fosfomycin susceptible and resistant isolates despite reports of single colony 278 
generation within the zone of inhibition.(31) A beneficial next step might be to directly 279 
compare micro-broth dilution and E-test methods to disc-diffusion assays to establish 280 
the most robust and practical method for determining fosfomycin susceptibilities 281 
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within a clinical laboratory setting and to assess the reproducibility each method for 282 
those deemed susceptible and resistant. Interpretation of E-tests was obfuscated by 283 
an intermediate zone of growth, resembling in appearance a ‘small’ colony phenotype 284 
observed at higher concentrations of fosfomycin when isolates were streaked onto 285 
plates. A similar ‘dual colony’ phenomenon in the presence of fosfomycin has been 286 
described previously by Tsuruoka et al. who reported differences in growth and 287 
carbohydrate uptake between colony types.(21) In the present study, these distinct 288 
phenotypes were found to be transient and inconsistent, large and small colonies 289 
going on after passage to produce daughter colonies of both phenotypes in the 290 
presence of higher concentrations of fosfomycin (data not shown) further hindering 291 
interpretation of susceptibility testing.  292 
In-silico MLST and whole genome comparison of the fosfomycin resistant E. coli 293 
showed that the isolates were of diverse sequence-types, and that resistance and 294 
plasmid profiles differed in each isolate. Therefore, resistance had not disseminated 295 
in this population due to expansion of one clone. Examination of the mechanisms of 296 
resistance found no evidence for mobile elements being involved in fosfomycin 297 
resistance, the absence of any plasmid located fos genes suggests that resistance in 298 
these E. coli were due to chromosomal mutations. When examining sequences of 299 
genes known to contribute to fosfomycin resistance, no two isolates had the same 300 
set of substitutions or mutations. As in other studies, changes in GlpT and 301 
UhpT/UhpA transport systems responsible for uptake of fosfomycin were the most 302 
commonly identified; with 6/8 resistant organisms possessing amino-acid changes or 303 
deletions within these systems that were absent in the susceptible strains. This 304 
included the complete deletion of the uhpT/uhpA region; location of a premature stop 305 
codon predicted to lead to a truncated UhpT protein; and the commonly reported 306 
UhpT substitution Glu350Gln;(14, 40) all speculated to result in reduced uptake of 307 
fosfomycin. Substitutions in GlpT were less common in this study than other recent 308 
reports, only a single isolate (MU721372) accumulating many changes in this region. 309 
Of note is the Glu448Lys substitution, identified previously in other fosfomycin 310 
resistant isolates.(14) This change was identified in all the sequenced isolates when 311 
compared to MG1655, including those deemed susceptible, but was not found during 312 
a search of an extended panel of sequenced E. coli submitted to Genbank. This 313 
suggests that either this substitution does not confer resistance to fosfomycin, 314 
contradicting speculation by others;(14) or that it acts to reduce susceptibility, 315 
perhaps below our defined breakpoints in the absence of other changes within the 316 
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protein. It may be that low-level changes to susceptibility account for why some 317 
isolates were deemed resistant using screening with the MAST Uri®system, whilst 318 
remaining sensitive using other testing methods.  319 
Only a single substitution (Val389Ile) was identified in MurA within the sequence of 320 
one of the susceptible isolates. Although the modification has been reported by others 321 
in fosfomycin resistant isolates,(40) its location outside the active site of this enzyme 322 
means its role in resistance is ambiguous. The role of changes in CyaA and PtsI 323 
proteins in this study is less clear. The amino-acid sequence of CyaA appeared to 324 
divide into two groups both with substitutions which can be found in other fosfomycin 325 
susceptible E. coli. This suggests that these changes may be unrelated to fosfomycin 326 
susceptibility but may correspond to the E. coli phylogeny.  327 
While many of the substitutions identified in this study have previously been linked to 328 
fosfomycin resistance by others, our detection of amino acid changes in both 329 
susceptible and non-susceptible strains raises doubts regarding their contribution to 330 
fosfomycin resistance. Mutations within the transport systems could be further 331 
investigated by growing these organisms on minimal media with or without glucose-332 
6-phosphate or glycerol-3-phosphate to elucidate their functional status.   333 
The use of fosfomycin for treatment of UTIs and other infections is likely to increase. 334 
In this study, the prevalence of fosfomycin resistance in E. coli isolated from UTIs 335 
was found to be relatively low and resistant isolates were divergent. The identification 336 
of chromosomal based changes in genes associated with fosfomycin susceptibility, 337 
and the absence of fos genes on conjugative plasmids indicates that resistance in 338 
these isolates was not transferrable, and that co-location with other resistance genes 339 
did not appear to lead to co-selection. Therefore, in this setting fosfomycin remains a 340 
useful agent in the treatment of UTIs, equipping us with an extra option for hard to 341 
treat UTIs and providing an alternative to drugs such as carbapenems which may 342 
drive selection of resistant organisms further. Current methods to identify fosfomycin 343 
resistant E. coli isolates in urine can give very different results, there is a need for 344 
more consistency to accurately define real rates of resistance which is important in 345 
monitoring any evolution of resistance as fosfomycin use is likely to increase. 346 
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Table 1: Fosfomycin minimum inhibitory concentrations and growth characteristics 496 
Isolate 
Fosfomycin MIC (µg/ml) 
MastUri BD Phoenix E-test 
MU721372 ≥32 64 512 (24) 
MU723051 ≥32 64 384 
MU715908 ≥32 64 384 (98) 
MU720214 ≥32 64 384 (48) 
MU723320 ≥32 64 256 
MU723292 ≥32 64 192 
MU720350 ≥32 32 256 
MU723240 ≥32 32 256 (12) 
MU720142 ≥32 32 96 (4) 
MU723432 ≥32 <16 0.38 
MU724857 ≥32 <16 0.75 
MU719876 ≥32 <16 0.25 
MU724367 ≥32 <16 0.19 
MU725806 ≥32 <16 0.5 
MU725463 ≥32 <16 0.25 
NCTC 10418 <16 <16 0.25 
J53-2   0.25 
 497 
MIC values in brackets represent interpretations of the E-test which include ‘intermediate’ growth within the zone of inhibition 498 
 499 
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Table 2: Genotypic characterisation of selected E. coli isolates 500 
Isolate Fosfomycin 
MIC (Phoenix) 
Serotype ST Antibiogram 
(Phoenix) 
Resfinder/ CARD: 
Presence of resistance genes 
Plasmid replicons 
MU721372 64 µg/ml O17/O77:
H18 
69 Fos, Amp, Trim blaTEM-1B, sul2, dfrA17, aph(6)Ib, 
aph(3’)Ib, 
IncFII, IncFIB, Col156, IncQ1 
MU723051 64 µg/ml O16:H5 131 Fos, Amp, Cefurox, 
Gent, Cipro 
blaTEM-1B, aac(3)-IId, gyrA IncFII, IncFIB, IncFIA 
MU715908 64 µg/ml O111:H21 40 Fos - - 
MU720214 64 µg/ml O6:H1 73 Fos, Amp, Trim blaTEM-1B, sul1, dfrA5 IncFIB, Col156 
MU723320 64 µg/ml O16:H5 131 Fos, Amp blaTEM-1B IncFII, IncFIB, Col156 
MU720350 32 µg/ml O75:H5 550 Fos - IncFII, IncFIB, IncX1, Col156, 
Col 
MU723240 32 µg/ml -:H4 131 Fos, Amp, Trim blaTEM-1B, sul1, dfrA17, aadA5, IncFII, IncFIA 
MU720142 32 µg/ml O6:H31 127 Fos, Amp, Trim blaTEM-1B, sul2, dfrA14, aph(3’)Ib, 
aph(6)Ib 
IncFII, IncFIB, IncB/O/Z/K, 
Col156 
MU723432 <16 µg/ml O83:H33 567 Amp, Trim blaTEM-1B, sul2, dfrA8, dfrA14, 
strB, aph(3’)Ib, aph(6)Ib, 
IncFII, IncFIB, IncFII(pCoo) 
MU724857 <16 µg/ml O25:H4 95 Amp, Coamox, 
PipTaz 
blaTEM-1B IncFII, ColpVC, IncFIB, 
IncB/O/Z/K 
Fos, fosfomycin; Amp, ampicillin; Trim, trimethoprim; Coamox, coamoxiclav; Cefurox, cefuroxime; Cipro, ciprofloxacin; Gent, gentamicin; PipTaz, Tazocin 501 
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       Table 3: Fosfomycin-associated mutations found in resistant E. coli isolates  502 
Isolate 
Fos MIC 
(Phoenix) 
Amino-acid substitutions or sequence variations 
MurA GlpT UhpT UhpA PstI CyaA 
MU721372 64 µg/ml None Leu297Phe 
Thr348Asn 
Glu443Gln 
None Arg14Gly 
Ala110Ser 
None Ser352Thr 
Ala349Glu 
Ser356Lys 
Gly359Glu 
MU723051 64 µg/ml None None Glu350Gln None Val25Ile None 
MU715908 64 µg/ml None None None None None None 
MU720214 64 µg/ml None None No peptide No peptide Ala306Thr Ala349Glu 
Ser356Lys 
Gly359Glu 
Ile514Val 
MU723320 64 µg/ml None None Glu350Gln None Val25Ile None 
MU720350 32 µg/ml None None Glu350Gln 
(Nonsense: premature stop 
codon at 31 and 39) 
None None Ala349Glu 
Ser356Lys 
Gly359Glu 
MU723240 32 µg/ml None None Tyr32Asn 
Arg325Leu 
Glu350Gln 
None None None 
MU720142 32 µg/ml None None None None None Ala349Glu 
Ser356Lys 
Gly359Glu 
Ile514Val 
MU723432 <16 µg/ml Val389Ile None None None None Ala349Glu 
Ser356Lys 
Gly359Glu 
Ile514Val 
MU724857 <16 µg/ml None Ala16Thr None Arg46Cys Ala306Thr Ala349Glu 
Ser356Lys 
Gly359Glu 
Present in all strains vs MG1655 None Glu448Lys None None Arg367Lys Asn142Ser 
503 
17 
 
24 
 
Figure Legend 504 
 505 
 506 
Figure 1. Phylogenetic reconstruction of population structure of the Fosfomycin 507 
resistant E. coli isolates produced by Roary. (R) and (S) indicate resistant and sensitive 508 
isolates respectively. ST121 strain EC958 was used as a reference. 509 
 510 
